Argenx acquires Forte for $2.2B for ph.2-stage vitiligo drug
Argenx acquires Forte for $2.2B for ph.2-stage vitiligo drug.
argenx
argenx is a antibodies company covered in the openbionews harvest.
Company Info
Recent News
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy.
Leadership Team
Careers & Job Openings